BioGaia AB (publ) - Asset Resilience Ratio
BioGaia AB (publ) (BIOG-B) has an Asset Resilience Ratio of 50.15% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read debt load of BioGaia AB (publ) for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2006–2025)
This chart shows how BioGaia AB (publ)'s Asset Resilience Ratio has changed over time. See net assets of BioGaia AB (publ) for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down BioGaia AB (publ)'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of BioGaia AB (publ).
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr801.31 Million | 50.15% |
| Short-term Investments | Skr0.00 | 0% |
| Total Liquid Assets | Skr801.31 Million | 50.15% |
Asset Resilience Insights
- Very High Liquidity: BioGaia AB (publ) maintains exceptional liquid asset reserves at 50.15% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
BioGaia AB (publ) Industry Peers by Asset Resilience Ratio
Compare BioGaia AB (publ)'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Daihan Pharmaceutical Co.Ltd
KQ:023910 |
Drug Manufacturers - Specialty & Generic | 11.95% |
|
Aurobindo Pharma Limited
NSE:AUROPHARMA |
Drug Manufacturers - Specialty & Generic | 16.92% |
|
China Resources Sanjiu Medical & Pharmaceutical Co Ltd
SHE:000999 |
Drug Manufacturers - Specialty & Generic | 5.22% |
|
Ningbo Menovo Pharm Co Ltd
SHG:603538 |
Drug Manufacturers - Specialty & Generic | 2.69% |
|
Zhejiang Xianju Pharmaceutical Co Ltd
SHE:002332 |
Drug Manufacturers - Specialty & Generic | 6.02% |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365 |
Drug Manufacturers - Specialty & Generic | 30.38% |
|
Hainan Honz Pharmaceutical Co
SHE:300086 |
Drug Manufacturers - Specialty & Generic | 0.27% |
|
Guangdong Lifestrong Pharmacy Co. Ltd.
SHE:301111 |
Drug Manufacturers - Specialty & Generic | 7.85% |
Annual Asset Resilience Ratio for BioGaia AB (publ) (2006–2025)
The table below shows the annual Asset Resilience Ratio data for BioGaia AB (publ).
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 50.15% | Skr801.31 Million ≈ $86.23 Million |
Skr1.60 Billion ≈ $171.95 Million |
-10.03pp |
| 2024-12-31 | 60.18% | Skr1.22 Billion ≈ $131.72 Million |
Skr2.03 Billion ≈ $218.89 Million |
-6.01pp |
| 2023-12-31 | 66.18% | Skr1.54 Billion ≈ $166.18 Million |
Skr2.33 Billion ≈ $251.09 Million |
-1.04pp |
| 2022-12-31 | 67.23% | Skr1.49 Billion ≈ $160.17 Million |
Skr2.21 Billion ≈ $238.26 Million |
-2.54pp |
| 2021-12-31 | 69.77% | Skr1.48 Billion ≈ $159.78 Million |
Skr2.13 Billion ≈ $229.01 Million |
-6.95pp |
| 2020-12-31 | 76.72% | Skr1.47 Billion ≈ $157.97 Million |
Skr1.91 Billion ≈ $205.90 Million |
+43.86pp |
| 2019-12-31 | 32.86% | Skr218.81 Million ≈ $23.55 Million |
Skr665.90 Million ≈ $71.66 Million |
-11.05pp |
| 2018-12-31 | 43.91% | Skr289.79 Million ≈ $31.19 Million |
Skr659.97 Million ≈ $71.02 Million |
-10.05pp |
| 2017-12-31 | 53.96% | Skr310.86 Million ≈ $33.45 Million |
Skr576.11 Million ≈ $62.00 Million |
+4.25pp |
| 2016-12-31 | 49.71% | Skr243.08 Million ≈ $26.16 Million |
Skr488.98 Million ≈ $52.62 Million |
+49.71pp |
| 2015-12-31 | 0.00% | Skr13.00K ≈ $1.40K |
Skr473.18 Million ≈ $50.92 Million |
0.00pp |
| 2014-12-31 | 0.00% | Skr13.00K ≈ $1.40K |
Skr415.61 Million ≈ $44.73 Million |
-0.02pp |
| 2013-12-31 | 0.02% | Skr80.00K ≈ $8.61K |
Skr383.42 Million ≈ $41.26 Million |
+0.01pp |
| 2012-12-31 | 0.02% | Skr80.00K ≈ $8.61K |
Skr517.02 Million ≈ $55.64 Million |
-0.01pp |
| 2011-12-31 | 0.03% | Skr80.00K ≈ $8.61K |
Skr279.83 Million ≈ $30.11 Million |
-0.01pp |
| 2010-12-31 | 0.04% | Skr80.00K ≈ $8.61K |
Skr227.82 Million ≈ $24.52 Million |
-0.01pp |
| 2009-12-31 | 0.04% | Skr80.00K ≈ $8.61K |
Skr179.81 Million ≈ $19.35 Million |
-0.52pp |
| 2007-12-31 | 0.56% | Skr620.00K ≈ $66.72K |
Skr110.77 Million ≈ $11.92 Million |
-0.35pp |
| 2006-12-31 | 0.91% | Skr830.00K ≈ $89.32K |
Skr90.76 Million ≈ $9.77 Million |
-- |
About BioGaia AB (publ)
BioGaia AB (publ), a healthcare company, develops, manufactures, markets and sells probiotic products for gut, oral, and immune health in Europe, the Middle East, Africa, the United States, the Asia-Pacific, Australia, and New Zealand. It operates through Pediatrics, Adult Health, and Other segments. The Pediatrics segment offers drops, oral rehydration solutions, and gut health tablets, as well … Read more